NanoBiCar: A novel immunotherapy for infectious diseasesbroad
NanoBiCar · Horizon Europe grant · 2025-02-01–2028-01-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2024-PATHFINDEROPEN-01-01. CORDIS record →
Objective
It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security. A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority. Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar's long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field. Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases will be used to eliminate intra (IC) and extracellular (EC) bacteria. These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/ acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host and the degree of immunocompetence.
Beneficiaries (12)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSITAT POLITECNICA DE VALENCIA | ES | coordinator | €755,436 | |
| TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY | IL | participant | €743,898 | |
| CELLULARIS BIOMODELS LDA | PT | participant | €538,438 | Yes |
| ACADEMISCH ZIEKENHUIS LEIDEN | NL | participant | €431,336 | |
| THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV | IL | participant | €371,981 | |
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | FR | participant | €296,120 | |
| INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL | ES | participant | €235,458 | |
| ACOSTA DOMINGUEZ ARMANDO | ES | participant | €72,620 | |
| SARMIENTO GARCIA SAN MIGUEL MARIA ELENA | ES | participant | €72,620 | |
| VICTOR PALLARUELO-SANTAMARIA | ES | participant | €72,620 | |
| FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPE | ES | thirdParty | €0 | |
| CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. | ES | thirdParty | €0 |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.